Resveratrol: Challenges in Translation to the Clinic — A Critical Discussion
Open accessAbstract
Low cancer survival rates and the serious side effects often associated with current chemotherapeutics highlight the need for new and effective nontoxic anticancer agents. Since 1997 when Jang and colleagues first described resveratrol's ability to inhibit carcinogenesis, it has consistently proven effective at tumor inhibition in diverse human cancer models. This finding has raised the hope that resveratrol would pioneer a novel class of nontoxic chemotherapeutics. As a consequence of initial basic and preclinical studies, resveratrol is now being extensively promoted in the unregulated nutraceutical sector. However, some fundamental aspects of resveratrol's action need to be understood before it can be developed into a clinically viable anticancer drug. These areas pertain to the key mechanism(s) by which resveratrol potentiates its antitumor effects. Current research suggests that these mechanisms might be through novel pathways, requiring an understanding of cellular uptake, sentinel targets, and in vivo biological networks. The metabolism of resveratrol and its bioavailablity also warrant further consideration in light of recent in vitro and in vivo studies. Finally, we need to appreciate the sorts of information about resveratrol that may translate between different disease entities. We present a critical discussion of these issues and suggest important experiments that could pave the way to the successful translation of resveratrol to the clinic.Clin Cancer Res; 16(24); 5942–8. ©2010 AACR.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The physiological effects of dietary resveratrol are in striking contrast to its poor bioavailability, which is a major concern for developing this class of compounds into therapeutic agents.
“Previous investigations have shown that the physiological effects of dietary RSV are in striking contrast to its poor bioavailability, which is a major concern for the development of this class of compounds into therapeutic agents (14, 15).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935 · cited 1× · see citing works
“In 1997, Jang and colleagues published their seminal report on resveratrol’s ability to inhibit the three major stages of carcinogenesis (1).”
BackgroundLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · see citing works
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., & Takada, Y. (2004) · PubMed · Cited by 1,383 · see citing works
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115 · see citing works
Substrate-specific activation of sirtuins by resveratrol
Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E. A., Caldwell, S. D., Napper, A., Curtis, R., DiStefano, P. S., Fields, S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500655200 · Cited by 745 · see citing works
Resveratrol stimulates AMP kinase activity in neurons
Dasgupta, B., & Milbrandt, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610068104 · Cited by 723 · see citing works
Marier, J., Vachon, P., Gritsas, A., Zhang, J., Moreau, J., & Ducharme, M. P. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033340 · Cited by 480 · see citing works
Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans
Bass, T. M., Weinkove, D., Houthoofd, K., Gems, D., & Partridge, L. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.07.007 · Cited by 436 · see citing works
Resveratrol is not a direct activator of SIRT1 enzyme activity
Beher, D., Wu, J., Cumine, S., Kim, K. W., Lu, S., Atangan, L., & Wang, M. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00901.x · Cited by 426 · see citing works
Inhibition of cancer growth by resveratrol is related to its low bioavailability
Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M. C., Obrador, E., & Estrela, J. M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00911-5 · Cited by 388 · see citing works
Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo
Garvin, S., Öllinger, K. M., & Dabrosin, C. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.031 · Cited by 351 · see citing works
Resveratrol: One molecule, many targets
Pirola, L., & Fröjdö, S. (2008) · IUBMB Life · doi:10.1002/iub.47 · Cited by 349 · see citing works
Human, Rat, and Mouse Metabolism of Resveratrol
Yu, C., Shin, Y. G., Chow, A. W., Li, Y., Kosmeder, J. W., Lee, Y. S., Hirschelman, W. H., Pezzuto, J. M., Mehta, R. G., & van Breemen, R. B. (2002) · Pharmaceutical Research · doi:10.1023/a:1021414129280 · Cited by 322 · see citing works
Kimura, Y., & Okuda, H. (2001) · Journal of Nutrition · doi:10.1093/jn/131.6.1844 · Cited by 311 · see citing works
Meng, X., Maliakal, P. P., Lu, H., Lee, M., & Yang, C. S. (2004) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf030582e · Cited by 281 · see citing works
Resveratrol Suppresses the Angiogenesis and Tumor Growth of Gliomas in Rats
Tseng, S.-H., Lin, S.-M., Chen, J.-C., Su, Y., Huang, H., Chen, C.-K., Lin, P.-Y., & Chen, Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0105 · Cited by 217 · see citing works
Gescher, A. J., & Steward, W. P. (2003) · PubMed · Cited by 210 · see citing works
Das, A., Banik, N. L., & Ray, S. K. (2009) · Cancer · doi:10.1002/cncr.24699 · Cited by 208 · see citing works
Resveratrol transport and metabolism by human intestinal Caco-2 cells
Kaldas, M. I., Walle, U. K., & Walle, T. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1211/002235702612 · Cited by 189 · see citing works
van Ginkel, P. R., Sareen, D., Subramanian, L., Walker, Q., Darjatmoko, S. R., Lindstrom, M. J., Kulkarni, A. D., Albert, D. M., & Polans, A. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0347 · Cited by 185 · see citing works
Self-citationLançon, A., Delma, D., Osman‐Ponchet, H., Thenot, J. P., & Latruffe, N. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.164 · Cited by 167 · see citing works
Sareen, D., Darjatmoko, S. R., Albert, D. M., & Polans, A. S. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.039040 · Cited by 159 · see citing works
Self-citationIntegrin αVβ3 contains a receptor site for resveratrol
Lin, H., Lansing, L., Mérillon, J., Davis, F. B., Tang, H., Shih, A., Vitrac, X., Krisa, S., Keating, T., Cao, H., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-5743fje · Cited by 145 · see citing works
Wang, L., Heredia, A., Song, H., Zhang, Z., Yu, B., Davis, C. E. L. B., & Redfield, R. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20156 · Cited by 129 · see citing works
Penumathsa, S. V., & Maulik, N. (2009) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y09-013 · Cited by 99 · see citing works
Maier‐Salamon, A., Hagenauer, B., Wirth, M., et al. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9060-z · Cited by 93 · see citing works
Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice
Zhou, H. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i2.280 · Cited by 93 · see citing works
Antitumor Activity of Resveratrol and its Sulfated Metabolites against Human Breast Cancer Cells
Miksits, M., Wlcek, K., Svoboda, M., Kunert, O., Haslinger, E., Thalhammer, T., Szekeres, T., & Jäger, W. R. (2009) · Planta Medica · doi:10.1055/s-0029-1185533 · Cited by 84 · see citing works
Wang, Z., Hsieh, T., Zhang, Z., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.174 · Cited by 75 · see citing works
Murias, M., Miksits, M., Aust, S., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.11.008 · Cited by 60 · see citing works
Resveratrol suppresses angiogenesis in gliomas: evaluation by color Doppler ultrasound.
Chen, J.-C., Chen, Y., Lin, J.-H., et al. (2006) · PubMed · Cited by 51 · see citing works
Review. Pro- and anti-angiogenesis effects of resveratrol.
Chen, Y., & Tseng, S. (2007) · PubMed · Cited by 49 · see citing works
Singh, S. K., Moretta, D., Almaguel, F. A., et al. (2007) · Growth Factors · doi:10.1080/08977190801886905 · Cited by 31 · see citing works
Analysis of the Resveratrol-binding Protein using Phage-displayed Random Peptide Library
Feng, L., Jin, J., Zhang, L., Yan, T., & Tao, W.-Y. (2006) · Acta Biochimica et Biophysica Sinica · doi:10.1111/j.1745-7270.2006.00163.x · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Chen, M.-L., Yi, L., Zhang, Y., Zhou, X., Ran, L., Yang, J., Zhu, J.-D., Zhang, Q.-Y., & Mi, M.-T. (2016) · mBio · doi:10.1128/mbio.02210-15 · Cited by 754 · see citing works
“In addition, the physiological effects of dietary RSV appeared to be in striking contrast to its poor bioavailability, which has been a major concern in the development of this class of compounds into therapeutic agents (14, 15).”
BackgroundGenetic and epigenetic regulation of human aging and longevity
Morris, B. J., Willcox, B. J., & Donlon, T. A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.039 · Cited by 140 · see citing works
Caloric restriction: Beneficial effects on brain aging and Alzheimer’s disease
Van Cauwenberghe, C., Vandendriessche, C., Libert, C., & Vandenbroucke, R. E. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9647-6 · Cited by 121 · see citing works
- Authors
- Subramanian, L., Youssef, S., Bhattacharya, S., Kenealey, J., Polans, A. S., & van Ginkel, P. R.
- Affiliations
- University of Wisconsin–Madison (US)
- Authors' Affiliations: 1Department of Ophthalmology and Visual Sciences, 2Eye Research Institute; 3Department of Biomolecular Chemistry, and 4Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin
- Venue
- Clinical Cancer Research
- Published
- 2010-12-15
- Volume
- 16
- Issue
- 24
- Pages
- 5942-5948
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3057445
- OpenAlex
- W2162672000
- Cited by
- 103
- References
- 34
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 5 · 2023: 1 · 2022: 5 · 2021: 10 · 2020: 6 · 2019: 8 · 2018: 5 · 2017: 6 · 2016: 7 · 2015: 12 · 2014: 8 · 2013: 13 · 2012: 4
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Center for Research Resources (UL1RR025011)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Biochemistry › Phytochemicals and Antioxidant Activities
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- resveratrol, anticancer agents, nutraceuticals, anticancer mechanism, cellular uptake, bioavailability, translational research, carcinogenesis inhibition
- MeSH terms
- Resveratrol, Animals, Antineoplastic Agents, Clinical Trials as Topic, Evaluation Studies as Topic, Humans, Models, Biological, Stilbenes, Drug Delivery Systems, Dietary Supplements, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
